Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 31, 2019updated 14 Nov 2021 1:15pm

Integra buys neurosurgical devices firm Arkis Biosciences

Medical technology company Integra LifeSciences has acquired neurosurgical devices maker Arkis Biosciences in a bid to boost its presence in neurocritical care and catheter technology markets.

Medical technology company Integra LifeSciences has acquired neurosurgical devices maker Arkis Biosciences in a bid to boost its presence in neurocritical care and catheter technology markets.

Arkis Biosciences’ portfolio includes the CerebroFlo external ventricular drainage (EVD) catheter featuring Endexo technology, which is a permanent additive intended to decrease catheter obstruction risk due to thrombus formation.

Endexo is claimed to minimise fibrinogen and platelet activation, as well as adhesion in the external ventricular management of cerebrospinal fluid (CSF).

Combination of EVD catheters with EVD systems is used for external CSF drainage in order to address increased ICP in acute brain injury and hydrocephalus patients.

Integra LifeSciences noted that catheter obstruction and bacterial colonisation are two main challenges associated with the external drainage of CSF in neurocritical care patients.

Arkis Biosciences CEO Chad Seaver said: “The introduction of the CerebroFlo EVD Catheter first established the benefits of Endexo in neurocritical care.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

“As a world leader in neurosurgery, Integra is the right choice to extend the reach of this important technology to patients and clinicians worldwide.”

Integra LifeSciences expects that the CerebroFlo EVD catheter will complement its Bactiseal Anti-Microbial EVD Catheters meant to reduce gram-positive bacterial colonisation on the catheter surface.

Bactiseal catheters provide protection for up to 28 days after implantation, added the company.

Codman Specialty Surgical president Dan Reuvers said: “Neurocritical care is an important area of focus for Integra. We recently introduced our CereLink Intracranial Pressure Monitor and invested in clinical specialists to better support neurocritical care teams.

“Today’s acquisition expands our leading portfolio to better treat patients and underscores our commitment to addressing unmet needs in-patient care.”

Codman Specialty Surgical is a portfolio of Integra LifeSciences. Financial details of the acquisition have not been disclosed.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU